# Page 107 Audit — Biographic & Disclosure Information: de Boer, Rossing, Caramori (11 Spans)

## Page Identity
- **PDF page**: S106 (Biographic and Disclosure Information — www.kidney-international.org)
- **Content**: Work Group Co-Chair biographies (Ian H. de Boer, Peter Rossing) + start of M. Luiza Caramori bio; conflict-of-interest disclosures (consultancy fees, grant support, speaker fees, stock options)
- **Clinical tier**: T3 (Informational — author biographies and disclosures)
- **Job ID**: df538e50-0170-4ef8-862d-5b0a7c48e4ff
- **Disagreement flag**: NO

## Extraction Summary
| Metric | Value |
|--------|-------|
| Total spans | 11 |
| T1 (Patient Safety) | 0 |
| T2 (Clinical Accuracy) | 11 |
| T3 (Informational) | 0 |
| Channels present | F (NuExtract LLM) |
| Tier accuracy | 0% (0/11) |
| Disagreements | 0 |
| Review Status | PENDING: 11 |
| Cross-Check | 2026-02-25 — counts verified against raw extraction data |
| Audit Date | 2026-02-25 (revised) |

## All Spans

| # | Text | Channel | Conf | Tier | Correct Tier | Issue |
|---|------|---------|------|------|-------------|-------|
| 1 | `<!-- PAGE 107 --> Biographic and disclosure information` | F | 90% | T2 | NOISE/BUG | **HTML artifact (11th occurrence)** + section title |
| 2 | "IHdB reports consultancy fees from AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Cyclerion Therapeutics, Geo..." | F | 85% | T2 | T3 | De Boer COI disclosure |
| 3 | "*Monies paid to institution." | F | 90% | T2 | T3 | Disclosure footnote |
| 4 | "and manager of the Steno Diabetes Center research team" | F | 90% | T2 | T3 | Rossing bio fragment |
| 5 | "dedicated to the research of microvascular and macrovascular complications of diabetes." | F | 90% | T2 | T3 | Rossing bio fragment |
| 6 | "He is the coordinator of the EU FP7 project PRIORITY, demonstrating that urinary proteomics can be used to stratify the ..." | F | 85% | T2 | T3 | Rossing research description |
| 7 | "PR reports consultancy fees from Astellas*" | F | 85% | T2 | T3 | Rossing COI disclosure |
| 8 | "grant support from AstraZeneca* and Novo Nordisk*" | F | 85% | T2 | T3 | Rossing COI disclosure |
| 9 | "speaker fees from AstraZeneca*, Boehringer Ingelheim*, Eli Lilly and Company*, and Novo Nordisk*" | F | 85% | T2 | T3 | Rossing COI disclosure |
| 10 | "educational presentations for Merck" | F | 85% | T2 | T3 | Rossing COI disclosure |
| 11 | "stock/stock options from Novo Nordisk" | F | 85% | T2 | T3 | Rossing COI disclosure |

### F Channel Extraction Pattern
The F channel (NuExtract LLM) has fragmented Rossing's COI disclosure into 5 separate spans (7-11), splitting at each category boundary (consultancy → grants → speaker → education → stock). This is consistent with the LLM treating each sentence clause as a discrete extractable entity.

### Why F Channel Extracted Biographical Content
The F channel appears to be triggered by pharmaceutical company names (AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, etc.) and medical terms ("microvascular and macrovascular complications") within the biographical text. However, these are in the context of author disclosures and research descriptions — not clinical recommendations.

## PDF Source Content
- **Ian H. de Boer, MD, MS** (Work Group Co-Chair): Professor at University of Washington; MD from Oregon Health Sciences; nephrology focus; director of Kidney Research Institute; 350+ manuscripts; ADA Professional Practice Committee 2016-2019; deputy editor CJASN
- **De Boer COI**: AstraZeneca, Bayer, Boehringer Ingelheim, Cyclerion, George Clinical, Goldfinch Bio, Eli Lilly, Medscape, Otsuka/Ironwood (consultancy); Dexcom*, JDRF*, Novo Nordisk* (grants)
- **Peter Rossing, MD, DMSc** (Work Group Co-Chair): Chief physician at Steno Diabetes Center; Professor at University of Copenhagen; internal medicine/endocrinology specialist; EU FP7 PRIORITY project coordinator; Minkowski prize 2005, Golgi prize 2016
- **Rossing COI**: Astellas*, AstraZeneca*, Bayer*, Boehringer Ingelheim*, Gilead*, Novo Nordisk* (consultancy); AstraZeneca*, Novo Nordisk* (grants); AstraZeneca*, Boehringer Ingelheim*, Eli Lilly*, Novo Nordisk* (speaker); Merck* (education); Novo Nordisk (stock)
- **M. Luiza Caramori, MD, PhD, MSc**: Associate professor at University of Minnesota; Brazilian medical degree; endocrinology/diabetes fellowship; DKD research training; JDRF sponsorship; Inpatient Diabetes Service director since 2016 (bio continues on next page)

## Quality Assessment
| Dimension | Rating | Notes |
|-----------|--------|-------|
| Tier accuracy | 0% | All should be T3 — biographies and COI disclosures |
| Clinical safety risk | NONE | Author biographies and financial disclosures |
| Key issue | F channel triggered by pharma company names in non-clinical context |
| Pipeline bugs | 1 | HTML artifact (11th confirmed occurrence) |

## Decision Recommendation
**ACCEPT** — Zero clinical safety risk. Author biographies and conflict-of-interest disclosures.

## Audit Metadata
- **Audited**: 2026-02-24
- **Method**: Playwright browser UI (Phase 2B Page Browse)
- **Auditor**: Claude (automated)
- **Page in sequence**: 107 of 126
